Physician profile
Jonathan A Phillips
NPI 1770088767
$4,083.45
in general payments reported to CMS, 2019-2025
27 companies · $1,627 in 2025
The $1,627 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $182 · 2023: $970 · 2024: $1,305 · 2025: $1,627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,901.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,901.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,244.24 | 2023-2025 | |
| Novo Nordisk INC | $608.36 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $435.41 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $420.92 | 2023-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $315.52 | 2023-2025 | Rexulti |
| Axsome Therapeutics, INC. | $234.34 | 2022-2025 | Auvelity |
| Glaxosmithkline, LLC. | $211.34 | 2023-2025 | Shingrix, Arexvy, Bexsero |
| Lilly USA, LLC | $94.61 | 2022-2025 | Zepbound, Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.48 | 2022-2025 | Xifaxan, Trulance |
| Exact Sciences Corporation | $70.11 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $54.84 | 2022-2024 | Verquvo, Belsomra, Gardasil |
| Corium, LLC | $37.96 | 2025 | Azstarys |
| Biohaven Pharmaceutical Holding Company LTD. | $34.52 | 2022 | |
| Lundbeck LLC | $28.98 | 2025 | Rexulti |
| Amgen INC. | $25.57 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $19.29 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.73 | 2024 | |
| Lifescan, INC. | $17.44 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $17.37 | 2025 | Eliquis |
| Astellas Pharma US INC | $15.92 | 2024 | Veozah |
| Pulmonx Corporation | $15.84 | 2023 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Harmony Biosciences LLC | $15.71 | 2023 | Wakix |
| Nevro Corp. | $14.91 | 2023 | Senza |
| Takeda Pharmaceuticals U.S.A., INC. | $14.13 | 2023 | Trintellix |
| Dexcom, INC. | $14.12 | 2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $13.53 | 2025 | Airsupra |
| Phathom Pharmaceuticals, INC. | $13.26 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.